This author has yet to write their bio.Meanwhile lets just say that we are proud SM contributed a whooping 83 entries.
Entries by SM
Micro cap Karyopharm Therapeutics (KPTI) announced positive results from its Phase 2/3 clinical trial, SEAL, assessing selinexor ((KPT-330)) in patients with previously treated, advanced, unresectable, dedifferentiated liposarcoma. Read the full brief in our Daily Pharma Scoop at SeekingAlpha Marketplace.
The Alcobra (ADHD) article in Seeking Alpha broadly says that though Alcobra is a company with a failed drug and no future prospects, it has a lot of cash and is selling below its NCAV or net current asset value. Read our full take in our SeekingAlpha Marketplace Daily Pharma Scoop.
Our daily analysis of a stock with a major event/upside: Intercept’s Letter Overblown Intercept (ICPT) saw a major slump last week, falling 20% from $110 to $85 or so, after the company’s CEO Dr Mark Pruzanski sent a “Dear Doctor” letter out to prescribing physicians of its Ocaliva medication telling them not to prescribe the […]
Alnylam Pharmaceuticals (ALNY) successfully completed a Phase 3 clinical trial, APOLLO, assessing RNAi therapeutic Patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy, and met its primary endpoint. Gets Analyst love: Analyst Action Rating Target Cowen and Company Reiterates Outperform $93.00 -> $117.00 JMP Securities Raises Target Outperform $101.00 -> $128.00 Needham & Company LLC […]
Citigroup reiterates buy on Allergan PLC. (AGN) with target of $280, while Morgan Stanley downgrades AGN from overweight to equal weight, revising target from $284 to $228. Could impact the share price. Check out more ratings on our SeekingAlpha Marketplace Daily Pharma Scoop.
Gemphire Therapeutics (GEMP) announces plans to advance gemcabene into Phase 3 clinical development after data showed clinically meaningful reductions in LDL-C and hsCRP across multiple trials. The micro cap stock rose 13% in low volume, in after hours trade. Check out detailed news in our Daily Pharma Scoop at SeekingAlpha Marketplace.
Insider sales at Athersys, Inc. (ATHX). Pres, COO -$35,726 Exec Vice Pres, CSO -$32,508 Check out all pharma insider sales in our SeekingAlpha Marketplace Daily Pharma Scoop.